Board WHOcte. Soft tissue and bone tumours. 5th ed edn.: World Health Organization

Weinstein JM, Drolet BA, Esterly NB, et al. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol. 2003;139:207–11.

Article  PubMed  Google Scholar 

Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56:968–73.

Article  PubMed  Google Scholar 

Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med. 2014;3:1404–15.

Article  PubMed  PubMed Central  Google Scholar 

Chan T-C, Wu C-J, Jeng S-F. Dermatofibrosarcoma protuberans: a 10-year experience. Formos J Surg. 2015;48:10–6.

Article  Google Scholar 

Li Y, Wang C, Yang K, et al. Clinical features of dermatofibrosarcoma protuberans and risk factors for local recurrence after Mohs micrographic surgery. J Am Acad Dermatol. 2020;82:1219–21.

Article  PubMed  Google Scholar 

Diwakar DK, Wadhwani N, Paruthi S. Recurrent dermatofibrosarcoma protuberans: challenging a surgeon’s dexterity for the “tricky” margins. Ecancermedicalscience. 2018;12:858.

PubMed  PubMed Central  Google Scholar 

Amjadzadeh M, Mousavi GP. Patient with recurrence dermatofibrosarcoma protuberans. Clin Case Rep. 2020;8:1192–4.

Article  PubMed  PubMed Central  Google Scholar 

Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol. 2011;18:328–36.

Article  PubMed  Google Scholar 

Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM. Fibrosarcomatous (“High-Grade”) Dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.

Article  CAS  PubMed  Google Scholar 

Linos K, Kozel JA, Hurley MY, Andea AA. Review of the medical literature and assessment of current utilization patterns regarding the use of two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcoma protuberans and clear cell sarcoma. J Cutan Pathol. 2018;45:905–13.

Article  PubMed  Google Scholar 

Li N, Zhou T, Chen S, Yang R, Zhu Q, Feng Z. COL1A1-PDGFB gene fusion in dermatofibrosarcoma protuberans: a useful diagnostic tool and clinicopathological analysis. Int J Clin Exp Pathol. 2018;11:4052–9.

PubMed  PubMed Central  Google Scholar 

Takahira T, Oda Y, Tamiya S, et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol. 2007;20:668–75.

Article  CAS  PubMed  Google Scholar 

Shimizu A, O’Brien KP, Sjöblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59:3719–23.

CAS  PubMed  Google Scholar 

Wang C, Luo Z, Chen J, et al. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine (Baltimore). 2015;94: e773.

Article  PubMed  Google Scholar 

Han A, Chen EH, Niedt G, Sherman W, Ratner D. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol. 2009;145:792–6.

Article  CAS  PubMed  Google Scholar 

Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–14.

Article  CAS  PubMed  Google Scholar 

Navarrete-Dechent C, Mori S, Barker CA, Dickson MA, Nehal KS. Imatinib treatment for locally advanced or metastatic dermatofibrosarcoma protuberans: a systematic review. JAMA Dermatol. 2019;155:361–9.

Article  PubMed  PubMed Central  Google Scholar 

Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

Article  PubMed  PubMed Central  Google Scholar 

Shindo Y, Akiyama J, Yamaji K, Ishihara Y, Saida T, Takase Y. Establishment of a human dermatofibrosarcoma protuberans cell line: cytological characteristics. J Dermatol. 1989;16:355–60.

Article  CAS  PubMed  Google Scholar 

Gershwin ME, Lentz D, Owens RB. Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice. Exp Cell Biol. 1984;52:361–70.

CAS  PubMed  Google Scholar 

Oyama R, Kito F, Qiao Z, et al. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell Dev Biol Anim. 2019;55:62–73.

Article  CAS  PubMed  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2020;33:894–903.

Article  CAS  PubMed  Google Scholar 

Chan JY, Lee ECY, Li Z, Lee JY, Lim AH, Poon E. Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation. Hum Cell. 2023;36:2228–36.

Article  CAS  PubMed  Google Scholar 

Bonish BK, Foreman KE, Gutierrez-Steil C, Nickoloff BJ. Phenotype and proliferation characteristics of cultured spindle-shaped cells obtained from normal human skin and lesions of dermatofibroma, Kaposi’s sarcoma, and dermatofibrosarcoma protuberans: a comparison with fibroblast and endothelial cells of the dermis. J Dermatol Sci. 1997;16:52–8.

Article  CAS  PubMed  Google Scholar 

Akiyama T, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation. Hum Cell. 2023;36:2187–94.

Article  CAS  PubMed  Google Scholar 

Robin T, Capes-Davis A, Bairoch A. CLASTR: The Cellosaurus STR similarity search tool - a precious help for cell line authentication. Int J Cancer. 2020;146:1299–306.

Article  CAS  PubMed  Google Scholar 

Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510–9.

Article  CAS  PubMed  Google Scholar 

Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ono T, Noguchi R, Yoshimatsu Y, et al. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023;36:1804–12.

Article  CAS  PubMed  Google Scholar 

Aykul S, Martinez-Hackert E. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. Anal Biochem. 2016;508:97–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22:304–11.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated. EGFR-Mutated Advanced NSCLC. 2019;382:41–50.

Google Scholar 

VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot. 2011;64:525–31.

Article  CAS  Google Scholar 

Kamar FG, Kairouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res. 2013;3:5.

Article  PubMed  PubMed Central  Google Scholar 

Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.00006.

Article  PubMed  PubMed Central  Google Scholar 

Jensen C, Teng Y. Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci. 2020. https://doi.org/10.3389/fmolb.2020.00033.

Article  PubMed  PubMed Central  Google Scholar 

Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12:207–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Assay Drug Dev Technol. 2010;362:2260–70.

CAS  Google Scholar